Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RYTMthis companyRhythm Pharmaceuticals, Inc.	$111.78	-34.42×	25.76×	36.66×	-39.66×	-426.8%	89.7%	-101.2%	-103.6%	-72.8%	-51.2%	-1.7%	0.01×	0.29×	-9.33×	4.41×	0.0%	3	12.7	1	C-
BIOABioAge Labs Inc.	$5.58	-5.91×	1.75×	52.85×	-3.66×	53.5%	100.0%	-1031.5%	-896.1%	-29.6%	-33.4%	-17.3%	0.02×	2.3×	-133.11×	14.24×	0.0%	3	4.79	2	C+
BLTEBelite Bio, Inc	$159.00	-69.25×	6.96×	0×	-64.97×	-93.2%	0.0%	0.0%	0.0%	-10.1%	-10.9%	-0.7%	0×	4.57×	0×	50.02×	0.0%	2	250.43	1	D+
BMEABiomea Fusion, Inc.	$0.60	-1.05×	2.19×	0×	-0.17×	48.4%	0.0%	0.0%	0.0%	-209.1%	-166.2%	-108.7%	0.05×	0.9×	0×	5.23×	0.0%	0	-18.95	2	C+
BMRNBioMarin Pharmaceutical Inc.	$55.98	32.65×	1.87×	3.54×	18.73×	-87.5%	77.1%	16.6%	10.8%	5.7%	5.6%	6.4%	0.11×	-1.17×	48.95×	5.21×	0.0%	3	0.33	3	B
GPCRStructure Therapeutics Inc.	$21.42	-28.98×	2.72×	0×	-23.85×	-35.6%	0.0%	0.0%	0.0%	-9.3%	-18.9%	-5.5%	0×	5.69×	0×	24.81×	0.0%	1	9.92	2	C+
Peer median	—	-5.91×	2.19×	0×	-3.66×	-35.6%	0.0%	0.0%	0.0%	-10.1%	-18.9%	-5.5%	0.02×	2.3×	0×	14.24×	0.0%	2	4.79	2	—